The t(8;21) fusion protein contacts co-repressors and histone deacetylases to repress the transcription of the p14ARF tumor suppressor
- PMID: 12732181
- DOI: 10.1016/s1079-9796(03)00021-4
The t(8;21) fusion protein contacts co-repressors and histone deacetylases to repress the transcription of the p14ARF tumor suppressor
Abstract
The t(8;21) is one of the most frequent chromosomal translocations associated with acute leukemia. The translocation fuses the DNA binding domain of AML1 to nearly all of the ETO co-repressor. ETO associates with the mSin3 and N-CoR co-repressors as well as histone deacetylases 1, 2, and 3. Although this is one of the most frequent chromosomal translocations in acute leukemia, accounting for 10-15% of the cases of acute myeloid leukemia (AML), the direct targets for transcriptional regulation that stimulate leukemogenesis are unknown. We found that AML1-ETO repressed the promoter of p14(ARF) tumor suppressor in transient transfection assays and reduced endogenous levels of p14(ARF) expression in multiple cell types. Chromatin immunoprecipitation assays demonstrated that AML1-ETO bound to the p14(ARF) promoter. In acute myeloid leukemia samples containing the t(8;21), levels of p14(ARF) mRNA were markedly lower when compared to other acute myeloid leukemias. Therefore, p14(ARF) is a direct transcriptional target of AML1-ETO.
Similar articles
-
The t(8;21) fusion protein, AML1 ETO, specifically represses the transcription of the p14(ARF) tumor suppressor in acute myeloid leukemia.Nat Med. 2002 Jul;8(7):743-50. doi: 10.1038/nm726. Epub 2002 Jun 24. Nat Med. 2002. PMID: 12091906
-
[Effect of AML1-ETO Fusion Protein on Transcriptional Regulation of p14ARF].Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Aug;25(4):970-974. doi: 10.7534/j.issn.1009-2137.2017.04.002. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017. PMID: 28823253 Chinese.
-
ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex.Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10860-5. doi: 10.1073/pnas.95.18.10860. Proc Natl Acad Sci U S A. 1998. PMID: 9724795 Free PMC article.
-
Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S31-4. doi: 10.1007/s002800100302. Cancer Chemother Pharmacol. 2001. PMID: 11587363 Review.
-
The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.Haematologica. 1997 May-Jun;82(3):364-70. Haematologica. 1997. PMID: 9234595 Review.
Cited by
-
Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network.Cancer Res. 2009 Nov 1;69(21):8249-55. doi: 10.1158/0008-5472.CAN-09-1567. Epub 2009 Oct 13. Cancer Res. 2009. PMID: 19826043 Free PMC article.
-
Human DMTF1β antagonizes DMTF1α regulation of the p14(ARF) tumor suppressor and promotes cellular proliferation.Biochim Biophys Acta. 2015 Sep;1849(9):1198-208. doi: 10.1016/j.bbagrm.2015.07.009. Epub 2015 Jul 15. Biochim Biophys Acta. 2015. PMID: 26187004 Free PMC article.
-
p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death.Blood. 2008 Feb 15;111(4):2190-9. doi: 10.1182/blood-2007-06-093682. Epub 2007 Nov 1. Blood. 2008. PMID: 17975013 Free PMC article.
-
Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective.Leukemia. 2022 May;36(5):1203-1214. doi: 10.1038/s41375-022-01548-7. Epub 2022 Mar 30. Leukemia. 2022. PMID: 35354921 Review.
-
The evolving landscape in the therapy of acute myeloid leukemia.Protein Cell. 2013 Oct;4(10):735-46. doi: 10.1007/s13238-013-3057-2. Epub 2013 Aug 27. Protein Cell. 2013. PMID: 23982740 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials